Comparative study using oral solutions of bambuterol once daily or terbutaline three times daily in 2-5-year-old children with asthma

A systematic review of adverse drug events associated with administration of common asthma medications in children

“…Three studies clearly described a process to determine ADE causality [ 25 , 31 , 39 ], but no studies utilized a standardized method for assessing causality such as the WHO-UMC [ 60 ] or Naranjo [ 61 ] scales [ 62 ]. Nine studies described a process to determine severity of ADE [ 23 , 30 – 33 , 36 , 42 ], but no studies utilized a standardized method (e.g. NCC MERP for medical errors [ 63 ], or U.S. FDA definitions[ 64 ]).…”

Focal Seizures in a Child Receiving Terbutaline Sulfate: A Case Report

“…Furthermore, our patient was being administered a dose of 1 ml of the 0.3 mg/ml syrup three times a day, which was around the normal single dose of 0.075 mg/kg [11], with seizures occurring only up to twice a day for the initial two days. However, when there was an increase in the terbutaline dosage to 2 ml over the past day as given by the mother, it coincided with an increased rate of seizures to several time a day over the last 24 hours and also caused a mild tachycardia.…”

A review of once‐daily delivery of anti‐asthmatic drugs in children

“…Once‐daily oral bambuterol (20 mg in the evening) provided a highly effective, convenient, and less expensive alternative to twice‐daily inhaled salmeterol (50 µg each dose) for relief of nocturnal symptoms in adult patients treated with inhaled and/or oral steroids for moderate‐to‐severe asthma (42, 43). Two recent studies have compared in children with asthma the safety of bambuterol (an oral solution in 2–5‐year‐old children, of 10 mg in the evening; or tablets in 6–12‐year‐old children, 10 or 20 mg in the evening) to that of terbutaline three times daily for 1 year (44, 45). The two drugs showed a comparable and favorable safety profile.…”

“…Moreover, the efficacy variables (PEF or FEV , asthma symptoms, restlessness, other reported symptoms, use of inhaled β2‐agonists, night‐time awakenings) were similarly improved in both groups. Because of its 24‐h duration of action and its mode of delivery, the authors concluded that oral bambuterol should be the preferred bronchodilator agent in children (44, 45).…”